Antiphospholipid Syndrome.

The article presents the findings of a study on the efficacy of rituximab in the treatment of resistant antiphospholipid syndrome (APS) and its variant, catastrophic APS. Some of the most common therapies used include oral anticoagulants, corticosteroids, plasma exchange, intravenous immunoglobulins and cyclophosphamide. The administration of rituximab, an anti-CD20 monoclonal antibody, and its effect on the patients are discussed.